Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique

Cancer Statistics, 2005

Ahmedin Jemal, Thomas S. Murray, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2005 · 5.5K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

Gillian M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 2001 · 288 citations

Medicine, Oncology, Pharmacology +16

The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells

Chryso Kanthou, Gillian M. Tozer · Blood · 2002 · 282 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.

David J. Chaplin, George R. Pettit, S A Hill · PubMed · 1999 · 252 citations

Medicine, Oncology, Pharmacology +17

Endothelial-cell proliferation in experimental tumours

J. Denekamp, B. Hobson · British Journal of Cancer · 1982 · 240 citations · Full text

Medicine, Cell Biology, Oncology +13